Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Business Wire
- Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes -- Data supports differentiation of voclosporin versus legacy CNIs and potential best-in-class attributes -- Data to be presented at the Keystone Symposia Conference on Islet Cell Biology - VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced that an abstract has been accepted for presentation at the Keystone Symposia Conference on Islet Biology: From Gene to Cell to Micro-Organ in Santa Fe, New Mexico from January 27-31, 2020. The abstract will be presented by Dr. James D. Johnson, Professor of Medicine in the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia (
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options [Yahoo! Finance]Yahoo! Finance
- Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis [Yahoo! Finance]Yahoo! Finance
- Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisBusiness Wire
AUPH
Earnings
- 11/7/24 - Beat
AUPH
Sec Filings
- 12/9/24 - Form 4
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- AUPH's page on the SEC website